Kymera Therapeutics (KYMR) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

KYMR Stock Forecast

Kymera Therapeutics stock forecast is as follows: an average price target of $58.60 (represents a 44.12% upside from KYMR’s last price of $40.66) and a rating consensus of 'Buy', based on 13 wall street analysts offering a 1-year stock forecast.

KYMR Price Target

The average price target for Kymera Therapeutics (KYMR) is $58.60 based on 1-year price targets from 13 Wall Street analysts in the past 3 months, with a price target range of $65.00 to $55.00. This represents a potential 44.12% upside from KYMR's last price of $40.66.

KYMR Analyst Ratings

Buy

According to 13 Wall Street analysts, Kymera Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for KYMR stock is 0 'Strong Buy' (0.00%), 7 'Buy' (53.85%), 6 'Hold' (46.15%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Kymera Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Dec 05, 2024	Etzer Darout	BMO Capital	$55.00	$44.08	24.77%	35.27%
Dec 02, 2024	Derek Archila	Wells Fargo	$57.00	$48.53	17.44%	40.19%
Sep 27, 2024	Jeff Jones	Oppenheimer	$56.00	$49.47	13.20%	37.73%
Aug 26, 2024	Andy Chen	Wolfe Research	$65.00	$47.78	36.04%	59.86%
Aug 08, 2024	Andrew Fein	H.C. Wainwright	$60.00	$40.31	48.85%	47.57%
Jun 17, 2024	Andrew Fein	H.C. Wainwright	$46.00	$32.29	42.46%	13.13%
May 23, 2024	Edward Tenthoff	Piper Sandler	$56.00	$34.84	60.76%	37.73%
May 03, 2024	Jeff Jones	Oppenheimer	$52.00	$36.30	43.25%	27.89%
Jan 03, 2023		Wells Fargo	$42.00	$24.71	69.97%	3.30%
Dec 19, 2022		Morgan Stanley	$41.00	$27.05	51.56%	0.84%
Dec 16, 2022		Goldman Sachs	$52.00	$28.26	84.01%	27.89%
Dec 15, 2022		Leerink Partners	$31.00	$29.62	4.66%	-23.76%
Dec 06, 2022	Michael Turits	Morgan Stanley	$45.20	$29.11	55.27%	11.17%
Dec 06, 2022	Richard Law	Credit Suisse	$32.00	$29.11	9.93%	-21.30%
Aug 29, 2022		Morgan Stanley	$37.00	$31.81	16.32%	-9.00%
Aug 10, 2022		Credit Suisse	$61.00	$32.83	85.81%	50.02%
May 04, 2022		Morgan Stanley	$35.00	$21.00	66.67%	-13.92%
May 04, 2022		Credit Suisse	$60.00	$21.27	182.15%	47.57%
May 20, 2021	Eliana Merle	UBS	$80.00	$43.20	85.19%	96.75%

The latest Kymera Therapeutics stock forecast, released on Dec 05, 2024 by Etzer Darout from BMO Capital, set a price target of $55.00, which represents a 24.77% increase from the stock price at the time of the forecast ($44.08), and a 35.27% increase from KYMR last price ($40.66).

Kymera Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	2	3	8
Avg Price Target	$56.00	$56.00	$55.88
Last Closing Price	$40.66	$40.66	$40.66
Upside/Downside	37.73%	37.73%	37.43%

In the current month, the average price target of Kymera Therapeutics stock is $56.00, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 37.73% increase as opposed to Kymera Therapeutics's last price of $40.66. This month's average price target is down 0.00% compared to last quarter, and up 0.21% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Dec 05, 2024	BMO Capital		Market Perform	Initialise
Oct 31, 2024	Jefferies	Buy	Buy	Hold
Sep 27, 2024	Wolfe Research	Equal-Weight	Equal-Weight	Hold
Sep 27, 2024	Oppenheimer	Outperform	Outperform	Hold
Sep 09, 2024	Wolfe Research	Buy	Buy	Hold
Aug 26, 2024	Wolfe Research		Outperform	Upgrade
Aug 14, 2024	Morgan Stanley	Equal-Weight	Equal-Weight	Hold
Aug 12, 2024	Wells Fargo	Buy	Buy	Hold
Aug 12, 2024	Oppenheimer	Underperform	Underperform	Hold
Aug 12, 2024	Wells Fargo	Equal-Weight	Equal-Weight	Hold
Aug 08, 2024	H.C. Wainwright	Buy	Buy	Hold
Jun 17, 2024	Piper Sandler	Overweight	Overweight	Hold
Jun 17, 2024	Oppenheimer	Buy	Buy	Hold
Jun 17, 2024	H.C. Wainwright	Underperform	Underperform	Hold
Jun 17, 2024	H.C. Wainwright	Buy	Buy	Hold
May 24, 2024	Oppenheimer	Underperform	Underperform	Hold
May 24, 2024	Piper Sandler	Buy	Buy	Hold
May 23, 2024	Piper Sandler	Overweight	Overweight	Hold
May 13, 2024	Bank of America Securities	Neutral	Neutral	Hold
May 03, 2024	Oppenheimer	Outperform	Outperform	Hold
Feb 27, 2024	Piper Sandler	Overweight	Overweight	Hold
May 04, 2023	Raymond James		Outperform	Upgrade
Jan 03, 2023	Wells Fargo	Overweight	Overweight	Hold
Dec 19, 2022	Morgan Stanley	Equal-Weight	Equal-Weight	Hold
Dec 16, 2022	Goldman Sachs	Buy	Buy	Hold
Dec 15, 2022	SVB Leerink	Market Perform	Market Perform	Hold
Dec 06, 2022	Credit Suisse	Outperform	Neutral	Downgrade
Aug 29, 2022	Morgan Stanley	Equal-Weight	Equal-Weight	Hold
Aug 10, 2022	Credit Suisse	Outperform	Outperform	Hold

Kymera Therapeutics's last stock rating was published by BMO Capital on Dec 05, 2024. The company Initialise its KYMR rating from "null" to "Market Perform".

Kymera Therapeutics Financial Forecast

Kymera Therapeutics Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
Revenue	-	-	-	-	-	-	-	-	-	$4.73M	$16.51M	$9.47M	$16.14M	$9.55M	$11.51M	$9.62M	$15.28M	$20.34M	$18.52M	$18.70M	$12.79M	$14.53M
Avg Forecast	$10.41M	$18.27M	$14.87M	$14.92M	$14.36M	$10.34M	$12.55M	$14.24M	$41.94M	$15.97M	$14.06M	$14.15M	$22.05M	$15.51M	$14.24M	$18.75M	$21.31M	$19.61M	$18.81M	$19.05M	$21.60M	$84.00M
High Forecast	$37.45M	$65.73M	$53.51M	$25.31M	$72.07M	$10.45M	$12.55M	$14.24M	$95.22M	$32.68M	$50.58M	$50.93M	$79.35M	$15.51M	$14.24M	$18.75M	$21.31M	$19.61M	$18.81M	$19.05M	$21.60M	$84.00M
Low Forecast	$3.41M	$5.99M	$4.88M	$11.44M	$2.68M	$10.23M	$12.55M	$14.24M	$10.31M	$8.00M	$4.61M	$4.64M	$7.24M	$15.51M	$14.24M	$18.75M	$21.31M	$19.61M	$18.81M	$19.05M	$21.60M	$84.00M
# Analysts	4	4	4	6	14	9	9	9	10	15	9	9	13	13	13	13	7	7	7	7	9	9
Surprise %	-	-	-	-	-	-	-	-	-	0.30%	1.17%	0.67%	0.73%	0.62%	0.81%	0.51%	0.72%	1.04%	0.98%	0.98%	0.59%	0.17%

Kymera Therapeutics's average Quarter revenue forecast for Dec 23 based on 10 analysts is $41.94M, with a low forecast of $10.31M, and a high forecast of $95.22M. KYMR's average Quarter revenue forecast represents a 787.07% increase compared to the company's last Quarter revenue of $4.73M (Sep 23).

Kymera Therapeutics EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	4	4	4	6	14	9	9	9	10	15	9	9	13	13	13	13	7	7	7	7	9	9
EBITDA	-	-	-	-	-	-	-	-	-	$-57.51M	$-43.38M	$-40.87M	$-34.81M	$-42.20M	$-39.51M	$-35.96M	$-33.16M	$-27.84M	$-24.08M	$-12.57M	$-12.16M	$-7.47M
Avg Forecast	$-10.41M	$-18.27M	$-14.87M	$-14.92M	$-14.36M	$-10.34M	$-12.55M	$-53.18M	$-41.94M	$-15.97M	$-14.06M	$-42.04M	$-30.72M	$-15.51M	$-14.24M	$-33.23M	$-21.31M	$-19.61M	$-18.81M	$-10.09M	$-21.60M	$-5.55M
High Forecast	$-3.41M	$-5.99M	$-4.88M	$-11.44M	$-2.68M	$-10.23M	$-12.55M	$-42.54M	$-10.31M	$-8.00M	$-4.61M	$-33.63M	$-24.57M	$-15.51M	$-14.24M	$-26.59M	$-21.31M	$-19.61M	$-18.81M	$-8.07M	$-21.60M	$-4.44M
Low Forecast	$-37.45M	$-65.73M	$-53.51M	$-25.31M	$-72.07M	$-10.45M	$-12.55M	$-63.81M	$-95.22M	$-32.68M	$-50.58M	$-50.45M	$-36.86M	$-15.51M	$-14.24M	$-39.88M	$-21.31M	$-19.61M	$-18.81M	$-12.11M	$-21.60M	$-6.66M
Surprise %	-	-	-	-	-	-	-	-	-	3.60%	3.09%	0.97%	1.13%	2.72%	2.78%	1.08%	1.56%	1.42%	1.28%	1.25%	0.56%	1.35%

undefined analysts predict KYMR's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Kymera Therapeutics's previous annual EBITDA (undefined) of $NaN.

Kymera Therapeutics Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	4	4	4	6	14	9	9	9	10	15	9	9	13	13	13	13	7	7	7	7	9	9
Net Income	-	-	-	-	-	-	-	-	-	$-52.87M	$-38.80M	$-36.59M	$-34.05M	$-41.12M	$-39.70M	$-36.44M	$-33.95M	$-28.58M	$-24.66M	$-13.07M	$-12.69M	$-7.99M
Avg Forecast	$-71.40M	$-62.52M	$-63.75M	$-59.74M	$-58.95M	$-63.36M	$-51.87M	$-54.26M	$-30.72M	$-48.48M	$-48.38M	$-42.89M	$-31.40M	$-55.51M	$-50.19M	$-33.90M	$-34.09M	$-26.84M	$-18.93M	$-10.50M	$-3.77M	$-5.93M
High Forecast	$-9.04M	$-7.91M	$-8.07M	$-53.25M	$-6.21M	$-8.02M	$-6.56M	$-43.40M	$31.42M	$-31.65M	$-6.12M	$-34.31M	$-25.12M	$-55.51M	$-50.19M	$-27.12M	$-34.09M	$-26.84M	$-18.93M	$-8.40M	$-3.77M	$-4.75M
Low Forecast	$-312.54M	$-273.68M	$-279.08M	$-64.94M	$-78.35M	$-277.35M	$-227.04M	$-65.11M	$-60.04M	$-60.60M	$-211.80M	$-51.47M	$-37.68M	$-55.51M	$-50.19M	$-40.69M	$-34.09M	$-26.84M	$-18.93M	$-12.60M	$-3.77M	$-7.12M
Surprise %	-	-	-	-	-	-	-	-	-	1.09%	0.80%	0.85%	1.08%	0.74%	0.79%	1.07%	1.00%	1.06%	1.30%	1.25%	3.36%	1.35%

Kymera Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. KYMR's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Kymera Therapeutics SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	4	4	4	6	14	9	9	9	10	15	9	9	13	13	13	13	7	7	7	7	9	9
SG&A	-	-	-	-	-	-	-	-	-	$14.12M	$14.13M	$12.56M	$11.64M	$10.56M	$11.03M	$10.61M	$11.74M	$10.67M	$8.03M	$5.91M	$5.17M	$6.84M
Avg Forecast	$11.22M	$19.70M	$16.04M	$16.09M	$15.48M	$11.15M	$13.54M	$15.35M	$45.22M	$17.22M	$15.16M	$12.41M	$10.87M	$16.73M	$15.35M	$9.81M	$22.98M	$21.15M	$20.29M	$4.74M	$23.29M	$5.08M
High Forecast	$40.38M	$70.87M	$57.70M	$27.29M	$77.71M	$11.26M	$13.54M	$15.35M	$102.68M	$35.24M	$54.54M	$14.89M	$13.05M	$16.73M	$15.35M	$11.77M	$22.98M	$21.15M	$20.29M	$5.69M	$23.29M	$6.10M
Low Forecast	$3.68M	$6.46M	$5.26M	$12.34M	$2.89M	$11.03M	$13.54M	$15.35M	$11.12M	$8.63M	$4.97M	$9.92M	$8.70M	$16.73M	$15.35M	$7.85M	$22.98M	$21.15M	$20.29M	$3.80M	$23.29M	$4.06M
Surprise %	-	-	-	-	-	-	-	-	-	0.82%	0.93%	1.01%	1.07%	0.63%	0.72%	1.08%	0.51%	0.50%	0.40%	1.25%	0.22%	1.35%

Kymera Therapeutics's average Quarter SG&A projection for Dec 23 is $45.22M, based on 10 Wall Street analysts, with a range of $11.12M to $102.68M. The forecast indicates a 220.28% rise compared to KYMR last annual SG&A of $14.12M (Sep 23).

Kymera Therapeutics EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	4	4	4	6	14	9	9	9	10	15	9	9	13	13	13	13	7	7	7	7	9	9
EPS	-	-	-	-	-	-	-	-	-	$-0.90	$-0.67	$-0.63	$-0.59	$-0.75	$-0.77	$-0.71	$-0.66	$-0.56	$-0.55	$-0.29	$-0.29	$-0.39
Avg Forecast	$-0.94	$-0.82	$-0.84	$-0.78	$-0.77	$-0.83	$-0.68	$-0.72	$-0.40	$-0.64	$-0.64	$-0.68	$-0.63	$-0.76	$-0.69	$-0.67	$-0.47	$-0.37	$-0.26	$-0.15	$-0.05	$0.72
High Forecast	$-0.12	$-0.10	$-0.11	$-0.70	$-0.08	$-0.11	$-0.09	$-0.09	$0.41	$-0.42	$-0.08	$-0.09	$-0.08	$-0.76	$-0.69	$-0.67	$-0.47	$-0.37	$-0.26	$-0.15	$-0.05	$0.72
Low Forecast	$-4.11	$-3.60	$-3.67	$-0.85	$-1.03	$-3.64	$-2.98	$-3.15	$-0.79	$-0.80	$-2.78	$-2.99	$-2.76	$-0.76	$-0.69	$-0.67	$-0.47	$-0.37	$-0.26	$-0.15	$-0.05	$0.72
Surprise %	-	-	-	-	-	-	-	-	-	1.41%	1.05%	0.92%	0.94%	0.99%	1.12%	1.06%	1.41%	1.52%	2.12%	1.96%	5.61%	-0.54%

According to undefined Wall Street analysts, Kymera Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to KYMR previous annual EPS of $NaN (undefined).

Kymera Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
STTK	Shattuck Labs	$1.15	$12.00	943.48%	Hold
CCCC	C4 Therapeutics	$4.05	$20.00	393.83%	Buy
PRLD	Prelude Therapeutics	$0.89	$4.00	349.44%	Sell
IPSC	Century Therapeutics	$1.17	$5.00	327.35%	Buy
CGEM	Cullinan Oncology	$11.49	$34.00	195.91%	Buy
FHTX	Foghorn Therapeutics	$5.51	$14.00	154.08%	Buy
MLYS	Mineralys Therapeutics	$12.35	$30.00	142.91%	Buy
NRIX	Nurix Therapeutics	$21.18	$32.67	54.25%	Buy
EWTX	Edgewise Therapeutics	$30.17	$46.25	53.30%	Buy
RVMD	Revolution Medicines	$45.16	$65.67	45.42%	Buy
KYMR	Kymera Therapeutics	$42.30	$58.60	38.53%	Buy
AGIO	Agios Pharmaceuticals	$41.96	$53.50	27.50%	Buy

KYMR Forecast FAQ

Is Kymera Therapeutics a good buy?

Yes, according to 13 Wall Street analysts, Kymera Therapeutics (KYMR) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 7 'Buy' recommendations, accounting for 53.85% of KYMR's total ratings.

What is KYMR's price target?

Kymera Therapeutics (KYMR) average price target is $58.6 with a range of $55 to $65, implying a 44.12% from its last price of $40.66. The data is based on 13 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Kymera Therapeutics stock go up soon?

According to Wall Street analysts' prediction for KYMR stock, the company can go up by 44.12% (from the last price of $40.66 to the average price target of $58.6), up by 59.86% based on the highest stock price target, and up by 35.27% based on the lowest stock price target.

Can Kymera Therapeutics stock reach $60?

KYMR's highest twelve months analyst stock price target of $65 supports the claim that Kymera Therapeutics can reach $60 in the near future.

What is Kymera Therapeutics's current price target trend?

2 Wall Street analysts forecast a $56 price target for Kymera Therapeutics (KYMR) this month, up 37.73% from its last price of $40.66. Compared to the last 3 and 12 months, the average price target increased by 37.73% and increased by 37.43%, respectively.

What are Kymera Therapeutics's analysts' financial forecasts?

Kymera Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $51.49M (high $109.31M, low $39.7M), average EBITDA is $-90.429M (high $-68.001M, low $-159M), average net income is $-228M (high $-64.192M, low $-648M), average SG&A $55.52M (high $117.86M, low $42.8M), and average EPS is $-3.009 (high $-0.364, low $-10.809). KYMR's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $58.47M (high $181.99M, low $25.73M), average EBITDA is $-58.467M (high $-25.732M, low $-182M), average net income is $-257M (high $-78.267M, low $-930M), average SG&A $63.04M (high $196.24M, low $27.75M), and average EPS is $-3.381 (high $-1.028, low $-12.22).

Did the KYMR's actual financial results beat the analysts' financial forecasts?

Based on Kymera Therapeutics's last annual report (Dec 2022), the company's revenue was $46.83M, which missed the average analysts forecast of $70.55M by -33.63%. Apple's EBITDA was $-155M, beating the average prediction of $-93.698M by 65.03%. The company's net income was $-152M, missing the average estimation of $-171M by -11.21%. Apple's SG&A was $43.83M, missing the average forecast of $52.76M by -16.92%. Lastly, the company's EPS was $-2.82, beating the average prediction of $-2.745 by 2.72%. In terms of the last quarterly report (Sep 2023), Kymera Therapeutics's revenue was $4.73M, missing the average analysts' forecast of $15.97M by -70.40%. The company's EBITDA was $-57.509M, beating the average prediction of $-15.972M by 260.06%. Kymera Therapeutics's net income was $-52.867M, beating the average estimation of $-48.478M by 9.05%. The company's SG&A was $14.12M, missing the average forecast of $17.22M by -18.01%. Lastly, the company's EPS was $-0.9, beating the average prediction of $-0.637 by 41.33%